Health Condition 1: null- Psoriasis Vulgaris
Conditions
Interventions
Intervention1: oral route of administration of methotrxate: Psoriasis patients who fulfil the criteria will be randomised to two groups and will receive treatment as per protocol and we will compare
Sponsors
Postgraduate Institute of Medical Education and Research
Prof Sunil Dogra
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients aged more than 18 years with clinical diagnosis of plaque psoriasis 2)Patients with body surface area involvement > 10 %, PASI >10,
Exclusion criteria
Exclusion criteria: 1) Hemoglobin 2) Elevation of hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or γ glutamyl transferase [GGT]) to more than twice the upper limit of normal. 3) Hepatitis, active or recurrent, cirrhosis or excessive current alcohol intake . 4) Use of other hepatotoxic drugs by the patient 5) Positive hepatitis B, hepatitis C or HIV serology 6) Pulmonary or extra-pulmonary active tuberculosis 7) Deranged renal function test. 8) Pregnancy or lactation or if patient is planning to conceive during the treatment period. 9) Patient on other immunosuppressive drugs 10) Recent live vaccination 11) Unreliable patient 12) Patients unwilling for monthly follow-ups.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the percentage of patients who achieved PASI 90 (90 % reduction in psoriasis area severity score (PASI) compared to baseline) in both the groupsTimepoint: 0 Weeks and 12 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Improvement in DLQI (dermatology life quality index). 2.Relapse free period after stopping treatment. 3.Adverse events if any. Timepoint: baseline and 12 weeks Follow up after treatment 6 months | — |
Countries
India
Contacts
Public ContactDr Tarun Narang
Post graduate Institute of Medical Education and research
Outcome results
None listed